Ligand Pharmaceuticals Incorporated

NASDAQ:LGND

Biotechnology

Healthcare
$298.71 +1.10%

+$2.89 today

Market cap
$5.98B
Beta
1.04
P/E (TTM)
34.4
EPS (TTM)
$7.72
52W Low $110.00High $268.43

Volume 0.38M

Average 0.22M

LGND Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Ligand Pharmaceuticals IncorporatedNASDAQ: LGND

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares grows in line with its trailing trend

Q2 FY2026 weighted avg shares of 20.06M shares rose 3.8% year over year, in line with the +4.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.8% toward the trailing-twelve-month pace of +4.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
20.06M+0.9% QoQ
Last fiscal yearDec 2025
19.34M+5.7% YoY
LTMJun 2026
19.76M+4.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.8%——
1 year+5.7%——
3-year CAGR+4.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
19.34M USD
Year-over-year change
+5.7%
4-year CAGR
+3.8%

Weighted Avg Shares vs competitors

How LGND compares with its peers on the latest reported figures

  • LGND's LTM Jun 2026 weighted avg shares of 19.76M shares is the 9th highest of the 10 companies compared; the peer median is 539.25M shares.
  • Its year-over-year change of +4.1% is the 2nd highest of 9, against a peer median of +0.4%.
  • Over three fiscal years its annual growth of +4.7% compares with a peer median of +0.0%.
LGND Competitors Peer median
Weighted Avg Shares for LGND and competitors
Company Period LTM YoY 3-year CAGR
PFEPfizer Inc.LTM Jun 20265.69B +0.3%+0.4%
BMYBristol-Myers Squibb CompanyLTM Jun 20262.04B +0.5%-1.4%
ABBVAbbVie Inc.LTM Sep 20261.77B +0.1%+0.1%
GMABGenmab A/SLTM Jun 2026614.84M —-1.7%
AMGNAmgen Inc.LTM Jun 2026539.25M +0.2%+0.0%
EXELExelixis, Inc.LTM Jul 2026262.28M -6.5%-5.5%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026229.47M +10.2%+4.1%
INCYIncyte CorporationLTM Jun 2026198.21M +2.5%-4.2%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 202619.76M +4.1%+4.7%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.08M +2.4%+1.4%
Peer median (excluding LGND) 539.25M+0.4%+0.0%

Competitors are the stored peer set for LGND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue241.54M196.25M131.31M167.13M268.09M
Cost of Revenue62.18M52.83M35.05M11.07M6.59M
Gross Profit179.37M143.42M96.27M156.06M261.5M
Gross Margin74.3%73.1%73.3%93.4%97.5%
Research & Development32.11M36.08M24.54M21.43M81.18M
Selling, General & Admin46.79M70.06M52.79M78.65M92.45M
Operating Expenses75.52M140.38M84.32M178.67M214.3M
Depreciation & Amortization50.95M43.39M36.52M35.24M33.78M
EBITDA142.77M81.2M100.84M40.79M192.74M
EBITDA Margin59.1%41.4%76.8%24.4%71.9%
Operating Income103.85M3.04M11.94M(22.61M)47.2M
Operating Margin43.0%1.5%9.1%-13.5%17.6%
Interest Income886K2.05M7.71M8.06M13.66M
Interest Expense19.62M1.8M656K3.04M4.72M
Other Income / Expenses(31.65M)32.97M51.72M25.12M111.76M
Income Before Tax72.21M36.01M63.66M2.52M158.96M
Pre-Tax Margin29.9%18.4%48.5%1.5%59.3%
Income Tax Expense(4.15M)41.23M9.84M6.55M34.51M
Net Income57.14M(33.36M)52.15M(4.03M)124.45M
Net Margin23.7%-17.0%39.7%-2.4%46.4%
EPS (Basic)3.46(1.98)3.02(0.22)6.44
EPS (Diluted)3.34(1.98)2.94(0.22)6.13
Weighted Avg Shares16.63M16.87M17.3M18.29M19.34M
Weighted Avg Shares (Diluted)17.25M16.87M17.76M18.29M20.29M

Ligand Pharmaceuticals Incorporated

NASDAQ:LGND

Intrinsic Alpha fair value

Locked

Current Price

$298.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.